EXAS:NSD-EXACT Sciences Corporation (USD)

COMMON STOCK | Diagnostics & Research |

Last Closing

USD 70.46

Change

+0.82 (+1.18)%

Market Cap

USD 12.84B

Volume

1.08M

Analyst Target

USD 116.50
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+3.25 (+0.73%)

USD 37.69B
ICLR ICON PLC

-4.51 (-1.94%)

USD 23.48B
ILMN Illumina Inc

+1.66 (+1.14%)

USD 22.77B
NTRA Natera Inc

+1.99 (+1.60%)

USD 14.84B
MEDP Medpace Holdings Inc

-11.41 (-3.46%)

USD 10.15B
RDNT RadNet Inc

-0.94 (-1.39%)

USD 4.95B
SHC Sotera Health Co

-0.09 (-0.57%)

USD 4.39B
NEOG Neogen Corporation

+0.23 (+1.60%)

USD 2.98B
GH Guardant Health Inc

+1.28 (+5.87%)

USD 2.52B
VCYT Veracyte Inc

+0.62 (+1.80%)

USD 2.50B

ETFs Containing EXAS

EKG First Trust Nasdaq Lux Di.. 4.56 % 0.00 %

+0.04 (+0.26%)

USD 2.49M
CDNA:CA CI Bio-Revolution Index E.. 2.68 % 0.00 %

N/A

CAD 6.10M
CURE:AU ETFS S&P Biotech ETF 2.55 % 0.00 %

+0.15 (+0.26%)

USD 0.04B
LABS 0.00 % 0.45 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

-0.42 (0.26%)

USD 0.91B
BTEC 0.00 % 0.42 %

N/A

N/A
TWOK 0.00 % 0.10 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

-0.14 (0.26%)

N/A
NIFE 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -4.76% 48% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -4.76% 48% F 40% F
Trailing 12 Months  
Capital Gain 10.93% 48% F 48% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.93% 48% F 49% F
Trailing 5 Years  
Capital Gain -21.70% 52% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -21.70% 52% F 37% F
Average Annual (5 Year Horizon)  
Capital Gain 6.63% 52% F 58% F
Dividend Return 6.63% 50% F 55% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 56.73% 54% F 33% F
Risk Adjusted Return 11.68% 60% D- 45% F
Market Capitalization 12.84B 91% A- 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.